Hansa Biopharma: (Q2 Initial Take): Stable Quarter After Transformative Serb Deal - Redeye

Redeye provides its first take on Hansa Biopharma's Q2 report. Total revenue was SEK48.1m (SEK49.1m in Q2 2025), up 39% sequentially from SEK34.6m in Q1 2026 and just around 9% below our previous forecast SEK53m. Operating costs were higher than we had expected, partly due to one-offs and non-cash costs.

Länk till analysen i sin helhet: https://www.redeye.se/research/1176755/hansa-biopharma-q2-initial-take-stable-quarter-after-transformative-serb-deal?utm_source=finwire&utm_medium=RSS